Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Open, multicenter phase I with gradual increase in dosage to evaluate the safety and
tolerability of orally administered nintedanib plus letrozole orally (2.5 mg / day) for
patients with breast cancer. Nintedanib is administered twice a day orally for 28 consecutive
days (Days 1-28) in 4-week cycles.
Phase:
Phase 1
Details
Lead Sponsor:
Centro Nacional de Investigaciones Oncologicas CARLOS III
Collaborators:
Dr, Ramón Colomer i Bosch Dr. Miguel Angel Quintela Fandiño (CNIO) FUNDACIÓN CRIS (Marta Cardona) as promotor